How do genetic variants result in
altered brain development and epilepsy?

A recent explosion in gene discovery has revealed hundreds of genes associated with intellectual disability and epilepsy.
There is a critical need to better understand how these gene variants cause disease
in order to develop novel therapeutic strategies.

Mission

To understand the cellular and molecular pathogenesis of genetic causes of epilepsy and brain malformations

Vision

To build a framework for pre-clinical development of novel therapies for children affected by genetic diseases of the brain

Values

Kindness
Integrity
Teamwork
Diversity
Curiosity

RESEARCH

Organoid models of mTORopathies

Pathogenic genetic variants in the mechanistic target of rapamycin (mTOR) pathway can cause mTOR hyperactivity, resulting in brain malformations and epilepsy. STRADA is an upstream regulator of the mTOR pathway, and loss of STRADA causes mTOR hyperactivation, and PMSE (polyhydramnios, megalencephaly, and symptomatic epilepsy) syndrome. We use human stem cell models, two- and three-dimensional neuronal cultures, multiple-electrode array recordings, and calcium imaging to determine how pathogenic variants in STRADA that result in mTOR pathway hyperactivation alter early cortical development and cause epilepsy.

Novel therapies for
​Dravet Syndrome

One of the most prevalent developmental and epileptic encephalopathies is Dravet Syndrome, caused by heterozygous loss of function variants in the SCN1A gene. This causes a reduction of the voltage gated sodium channel encoded by SCN1A, Nav1.1. In many genes, including SCN1A, there are start codons and open reading frames upstream of the primary start codon that can interfere with the efficiency of translation of the main protein product. We aim to target these upstream open reading frames to amplify expression of the non-pathogenic copy of SCN1A as a therapeutic strategy.

SCN1B-related developmental and epileptic encephalopathy

Biallelic pathogenic variants in the SCN1B gene cause a severe developmental and epileptic encephalopathy (DEE) that can have clinical features shared with Dravet Syndrome. In collaboration with Dr. Lori Isom and Dr. Jack Parent, we differentiate patient-derived stem cells into neuronal cultures in order to explore how pathogenic variants in SCN1B cause neuronal dysfunction and epilepsy.​

THE TEAM

We believe that science is best advanced by
a diverse team working in an inclusive and collaborative environment

Louis T. Dang, MD/PhD
​Principal Investigator

Pediatric epileptologist, developmental neurobiologist, rock climber

Grace Lin, PhD
Research Specialist

Molecular biologist, chromatin expert, baker extraordinaire
​

Debora VanHeyningen
​Research Specialist

Stem cell culturist, filk musician

Dan Jaklic, M.S.
Research Technician

Engineer, multi-electrode array hacker, organoid whisperer, triathlete

Sahej Kohli
Undergraduate student

​Histologist, basketballer

Lab Alumni

Daniel Klarr, 2016
Matthew Parent, summer 2016
Pooja Patel, summer 2017
Trevor Glenn, summer 2016 and summer 2017
Anand Chandrasekhar, 2017-2018
Alexandra (Lexie) Streicher, summer 2018 and summer 2019
Jordan Safran, 2017-2019
Monica Lee, summer 2020
Preethi Swaminathan, 2016-2020
Shivanshi Vaid, 2018-2022
Anna Loughman, 2019-2022

PUBLICATIONS


​

LAB NEWS

8/10/22

We are excited to have received our Notice of Award from the NIH for our R01 grant submission! A big thank you to all the mentors, collaborators, and sponsors that have contributed to this big milestone in our lab. 

Contact us

Dang Lab
Biomedical Science Research Building, Rm 5258
109 Zina Pitcher Place
Ann Arbor, MI 48109

​Email: louisdan [at] med.umich.edu
© Copyright Louis Dang